Cargando…

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia

Immune thrombocytopenia (ITP) is a disease of heterogenous origin characterized by low platelet counts and an increased bleeding tendency. Three disease phases have been described: newly diagnosed (≤ 3 months after diagnosis), persistent (> 3–12 months after diagnosis), and chronic (> 12 month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grainger, John D., Kühne, Thomas, Hippenmeyer, Jane, Cooper, Nichola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310729/ https://www.ncbi.nlm.nih.gov/pubmed/34308495 http://dx.doi.org/10.1007/s00277-021-04590-0

Ejemplares similares

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
por: Snell Taylor, Sara J., et al.
Publicado: (2021)

Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy
por: Murray, Nigel P., et al.
Publicado: (2020)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
por: Grainger, John, et al.
Publicado: (2022)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
por: Schifferli, Alexandra, et al.
Publicado: (2019)

Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
por: Reiser, Marcel, et al.
Publicado: (2021)

Adolescents and young adults with newly diagnosed primary immune thrombocytopenia
por: Schifferli, Alexandra, et al.
Publicado: (2023)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
por: Kuter, David J., et al.
Publicado: (2019)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
por: Perdomo, Jose
Publicado: (2016)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report
por: Kim, Hyun-Young, et al.
Publicado: (2019)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China
por: Zhou, Hu, et al.
Publicado: (2023)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
por: Gonzalez, Maria Fernanda, et al.
Publicado: (2012)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
por: Gellens, Romain, et al.
Publicado: (2018)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
por: Tarantino, Michael D., et al.
Publicado: (2019)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
por: McCall, Andrew N., et al.
Publicado: (2016)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
por: Buchbinder, David, et al.
Publicado: (2017)

Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Missing Cells-A Rare Case of Persisting Thrombocytopenia in Pregnancy With Dengue and Role of Romiplostim in These Cases
por: Sinha, Ruchita, et al.
Publicado: (2023)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kig6mgrdmj8ogrs61hcgkpnftr